Natera (NASDAQ:NTRA) Trading Down 2.1% – Should You Sell?

by · The Cerbat Gem

Natera, Inc. (NASDAQ:NTRA – Get Free Report)’s stock price traded down 2.1% on Wednesday . The company traded as low as $125.30 and last traded at $126.27. 140,776 shares changed hands during trading, a decline of 89% from the average session volume of 1,339,545 shares. The stock had previously closed at $129.00.

Wall Street Analyst Weigh In

Several analysts recently commented on NTRA shares. Robert W. Baird raised their price objective on shares of Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, August 9th. The Goldman Sachs Group boosted their price target on Natera from $125.00 to $140.00 and gave the stock a “buy” rating in a research note on Wednesday. Morgan Stanley raised their price objective on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research note on Tuesday, August 13th. StockNews.com upgraded Natera from a “sell” rating to a “hold” rating in a research report on Thursday. Finally, Leerink Partners lifted their price target on Natera from $140.00 to $150.00 and gave the stock an “outperform” rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and sixteen have issued a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $124.44.

Get Our Latest Analysis on NTRA

Natera Trading Down 3.5 %

The business has a 50 day simple moving average of $123.15 and a two-hundred day simple moving average of $110.16. The company has a current ratio of 4.14, a quick ratio of 4.01 and a debt-to-equity ratio of 0.34. The company has a market cap of $15.02 billion, a PE ratio of -39.21 and a beta of 1.53.

Natera (NASDAQ:NTRA – Get Free Report) last issued its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.69) by $0.39. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm had revenue of $413.35 million for the quarter, compared to analyst estimates of $343.00 million. During the same period last year, the company earned ($0.97) EPS. The firm’s quarterly revenue was up 58.1% on a year-over-year basis. On average, analysts forecast that Natera, Inc. will post -1.96 EPS for the current fiscal year.

Insider Buying and Selling

In other Natera news, insider Solomon Moshkevich sold 549 shares of Natera stock in a transaction on Monday, July 22nd. The shares were sold at an average price of $105.16, for a total value of $57,732.84. Following the transaction, the insider now owns 113,637 shares in the company, valued at $11,950,066.92. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. In other Natera news, CFO Michael Burkes Brophy sold 1,866 shares of Natera stock in a transaction that occurred on Wednesday, July 31st. The shares were sold at an average price of $99.65, for a total transaction of $185,946.90. Following the transaction, the chief financial officer now directly owns 71,955 shares of the company’s stock, valued at $7,170,315.75. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, insider Solomon Moshkevich sold 549 shares of the stock in a transaction on Monday, July 22nd. The stock was sold at an average price of $105.16, for a total transaction of $57,732.84. Following the completion of the sale, the insider now directly owns 113,637 shares of the company’s stock, valued at $11,950,066.92. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 50,765 shares of company stock valued at $6,016,700. Insiders own 7.60% of the company’s stock.

Institutional Trading of Natera

A number of institutional investors have recently added to or reduced their stakes in NTRA. Itau Unibanco Holding S.A. acquired a new position in shares of Natera during the second quarter worth about $28,000. Quarry LP grew its position in Natera by 148.4% in the second quarter. Quarry LP now owns 318 shares of the medical research company’s stock valued at $34,000 after acquiring an additional 190 shares in the last quarter. GAMMA Investing LLC raised its stake in shares of Natera by 50.0% during the second quarter. GAMMA Investing LLC now owns 324 shares of the medical research company’s stock valued at $35,000 after purchasing an additional 108 shares during the period. Tobam acquired a new position in shares of Natera during the second quarter worth $74,000. Finally, DekaBank Deutsche Girozentrale purchased a new position in shares of Natera in the first quarter valued at $83,000. 99.90% of the stock is owned by hedge funds and other institutional investors.

About Natera

(Get Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

Read More